| Literature DB >> 22615645 |
Abstract
BACKGROUND AND THE PURPOSE OF THE STUDY: Partition coefficients (log D and log P) and molecular surface area (PSA) are potential predictors of the intestinal permeability of drugs. The aim of this investigation was to evaluate and compare these intestinal permeability indicators.Entities:
Keywords: Biopharmaceutical classification system; PSA; Permeability; log D; log P
Year: 2011 PMID: 22615645 PMCID: PMC3232101
Source DB: PubMed Journal: Daru ISSN: 1560-8115 Impact factor: 3.117
BCS classification of the orally administered drugs on the list of national essential medicines (NEML) of Pakistan with their therapeutic classes, maximum doses, experimental water solubility, predicted aqueous solubility (ACD/Labs), pH dependent solubility (pKa), log D, calculated PSA, and interaction with transporters in the intestine.
| Provisional biopharmaceutical classification of drugs on the list of national essential medicines (NEML) of Pakistan. | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solubility | Permeability | BCS classification | ||||||||||||
| Drug | Therapeutic class | Maximum dose (mg) | Do | Do | Do | pKa | Log D6.0 | PSA | Transporters interaction | Solubility class | Permeability class | BCS Class | ||
| HA | BH+ | |||||||||||||
| NSAID | 300 | NA | 0.0012 | 3.48 | −1.24 | 63.6 | Pgp | High | Low | III | ||||
| Antiviral | 200 | NA | 2.1 | 9.18 | 1.89 | −1.76 | 109.83 | OATP1, OATP3, OCT1 | Low | Low | IV | |||
| Anthelmintic | 200 | NA | 13.3 | 10.46 | 5.62 | 2.87 | 92.31 | BCRP | Low | High | II | |||
| anti-gout | 300 | NA | 0.03 | 9.2 | 2.4 | −3.81 | 74.69 | NA | High | Low | III | |||
| Diuretic | 5 | NA | 0.16 | 8.58 | 1.58 | 1.07 | 156.79 | NA | High | High | I | |||
| Antiasthmatic | 200 | NA | 0.00002 | NA | NA | 192 | NA | High | Low | III | ||||
| Antiarrhythmic | 200 | 1.1 | 9.37 | 6.29 | 42.7 | MDR1 | Low | High | II | |||||
| Antipsychotic | 50 | NA | 0.14 | 9.24 | 2.08 | 3.24 | NA | High | High | I | ||||
| Antihypertensive | 5 | NA | 0.001 | 8.73 | 1.43 | 99.9 | MDR1 | High | High | I | ||||
| Antibacterial | 500 | NA | 6.66 | 2.61 | 6.93 | −1.93 | 158.26 | PEPT1 | Low | Low | IV | |||
| Antifungal | 100 | 0.5 | 3.96 | 8.13 | NA | 320 | NA | High | Low | III | ||||
| Antibacterial | 500 | 0.2 | 2.61 | 6.79 | −1.21 | 138 | PEPT1, OCTN2 | High | Low | III | ||||
| Anticancer | 1 | NA | 0.008 | 4.78 | 0.77 | 78.3 | NA | High | High | I | ||||
| Antihypertensive | 100 | NA | 0.0004 | 13.88 | 9.17 | −2.73 | 84.58 | MDR1 | High | Low | III | |||
| Antispasmodic | 1 | NA | 6.76E-06 | 9.88 | −1.52 | 49.77 | NA | High | Low | III | ||||
| Anticancer | 50 | 1.5 | 0.25 | −0.54 | 143 | NA | Low | Low | IV | |||||
| Antiparkinsonism | 2.5 | NA | 0.11 | 9.61 | 6.45 | 4.52 | 118 | MDR1 | High | High | I | |||
| Anticancer | 0.5 | NA | 1.20E-07 | NA | −0.52 | 104 | NA | High | Low | III | ||||
| Antihypertensive | 50 | NA | 0.0002 | 3.82 | −2.02 | 96.41 | MDR1: PEPT1 | High | Low | III | ||||
| Antiepileptic | 200 | NA | 10 | 13.94 | 2.67 | 46.33 | MDR1 | Low | High | II | ||||
| Antiparkinsonism | 25 | NA | 0.1 | 3.4 | 7.91 | −2.71 | 116 | NA | High | Low | III | |||
| Antibacterial | 100 | NA | 0.03 | 2.1 | 2.86 | −3.72 | 238 | NA | High | Low | III | |||
| Antibacterial | 250 | NA | 3.52 | 2.59 | −4.47 | 199 | PEPT1 | Low | Low | IV | ||||
| Antibacterial | 500 | 0.04 | 3.12 | 6.8 | −2.22 | 138 | PEPT1, PEPT2, | OCTN2 | High | Low | III | |||
| Antibacterial | 500 | 0.25 | 3.12 | 6.99 | −1.53 | 138 | OAT1, OCTN2, PEPT1 | High | Low | III | ||||
| Anticancer | 2 | 0.01 | 4.86 | 3.66 | 1.52 | 40.5 | MRP1 | High | High | I | ||||
| Antibacterial | 250 | NA | 4.3 | 11.03 | 1.02 | 115.38 | NA | Low | High | II | ||||
| Antimalarial | 150 | NA | 0.02 | 10.48 | 1.2 | 28.16 | MDR1 | High | High | I | ||||
| Antiallergic | 4 | NA | 0.0003 | 9.33 | 0.49 | 16.13 | NA | High | High | I | ||||
| Antipsychotic | 100 | NA | 0.44 | 9.43 | 2.28 | 31.78 | MDR1, OCT1 | High | High | I | ||||
| Antiulcer | 400 | NA | 0.14 | 6.73 | −1.14 | 114.19 | MDR1, OAT1, OAT3, OCT1, OCT3, OCTN2 | High | Low | III | ||||
| Antibacterial | 250 | NA | 0.77 | 2.74 | 8.76 | −1.07 | 72.88 | MDR1 | High | Low | III | |||
| Antileprosy | 100 | NA | 412.4 | 6.24 | 5.72 | 39.99 | MDR1 | Low | High | II | ||||
| Antipsychotic | 25 | NA | 0.09 | 9.49 | 2.58 | 6.48 | MDR1 | High | High | I | ||||
| Antileprosy | 100 | NA | 412.4 | 6.24 | 5.72 | 39.99 | MDR1 | Low | High | II | ||||
| Antibacterial | 250 | NA | 0.07 | NA | −0.81 | 138.04 | PEPT1 | High | Low | III | ||||
| anti-gout | 0.5 | NA | 0.03 | NA | 0.92 | 83.09 | MDR1, OCT3 | High | High | I | ||||
| Antihistamine | 50 | NA | 0.2 | 7.46 | 1.83 | 6.5 | NA | High | High | I | ||||
| Anticancer | 50 | NA | 0.002 | 4.09 | 0.23 | 51.38 | MDR1 | High | High | I | ||||
| Immunosuppressent | 100 | 10 | NA | NA | 279 | BCRP, MDR1, MRPs, OATP1B1 | Low | Low | IV | |||||
| Antileprosy | 50 | NA | 0.57 | 1.24 | 0.94 | 94.56 | NA | High | High | I | ||||
| Antiallergic | 0.5 | NA | 0.04 | 12.14 | 1.87 | 94.83 | MDR1, OATP1A2 | High | High | I | ||||
| Sedative | 10 | NA | 2 | 3.4 | 2.96 | 32.67 | MDR1 | Low | High | II | ||||
| Antiretroviral | 400 | NA | 0.81 | 8.67 | 1.98 | −1.33 | 83.81 | NA | High | Low | III | |||
| Cardiostimulant | 0.25 | NA | 0.002 | 13.5 | 0.85 | 203.06 | MDR1, OATP1B3, OATP1C1, OATP4C1, OST | High | High | I | ||||
| Anti-Amoebic | 500 | NA | 1.08 | NA | 1.62 | 40.54 | NA | Low | High | II | ||||
| Calcium channel blocker | 180 | NA | 0.006 | 8.91 | 2.64 | 84.4 | MDR1 | High | High | I | ||||
| Antibacterial | 100 | NA | 0.54 | 4.5 | 9.32 | −3.06 | 181.62 | OAT1, OAT3, OAT4 | High | Low | III | |||
| Antiretroviral | 50 | NA | 376.6 | 7.92 | 4.84 | 38.33 | NA | Low | High | II | ||||
| Antihypertensive | 10 | NA | 0.002 | 3.75 | 5.5 | −0.12 | 95.9 | MDR1, OATP1A2, PEPT1 | High | High | I | |||
| Oxytotic | 0.25 | NA | 0.00018 | NA | −0.54 | 68.36 | MDR1 | High | Low | III | ||||
| Antimigraine | 1 | NA | 0.4 | 9.62 | 7.2 | 1.99 | 118.21 | MDR1 | High | High | I | |||
| Antibacterial | 500 | NA | 0.08 | 13.08 | 8.14 | 0.72 | 193.91 | MDR1, MRP1, OAT2, OATP1A2 | High | High | I | |||
| Anti-tuberculosis | 400 | NA | 0.0016 | 9.6 | −3.23 | 64.52 | NA | High | Low | III | ||||
| Antiepileptic | 250 | NA | 0.042 | 9.7 | 0.38 | 46.17 | NA | High | High | I | ||||
| Anticancer | 100 | 2 | 9.95 | 1.96 | 161 | BCRP, MDR1−3,6,7, | Low | High | II | |||||
| Antipsychotic | 20 | NA | 0.002 | 10.05 | NA | 21.3 | MDR1 | High | High | I | ||||
| Anticancer | 250 | NA | 0.42 | 13.12 | NA | 74.9 | NA | High | High | I | ||||
| Diuretic | 40 | NA | 0.02 | 3.04 | 0.26 | 131.01 | MRP2, OAT1, OAT3, OAT4, OCTN2 | High | High | I | ||||
| Antihyperlipidemia | 300 | NA | 0.12 | 4.75 | 2.14 | 46.5 | NA | High | High | I | ||||
| Antidiabetic | 5 | NA | 1 | NA | 2.75 | 121.98 | BSEP, MDR1, MRP1, OATP2B1 | High | High | I | ||||
| Antifungal | 500 | NA | 2985.07 | NA | 3.53 | 71.06 | NA | Low | High | II | ||||
| Antipsychotic | 5 | NA | 0.006 | 13.9 | 8.25 | 0.82 | 40.54 | MDR1 | High | High | I | |||
| Antihypertensive | 25 | NA | 0.08 | NA | 0.56 | 63.83 | NA | High | High | I | ||||
| Diuretic | 50 | NA | 0.48 | 8.95 | −0.07 | 135.12 | NA | High | High | I | ||||
| NSAID | 600 | NA | 1.17 | 4.41 | 2.12 | 37.3 | MDR1, MRP1, MRP3, OAT1−4 | Low | High | II | ||||
| Antipsychotic | 25 | 5.5 | 9.49 | 1.85 | 6.5 | MDR1, OCT2, OCT3 | Low | High | II | |||||
| Antiretroviral | 400 | NA | 53.3 | 5.73 | 2.76 | 118.03 | MDR1, MRP1, MRP2, OATP1A2, OATP1B1 | Low | High | II | ||||
| NSAID | 25 | 6.25 | 4.17 | 0.3 | 68.5 | MDR1, MRP1-8, OAT1-4 | Low | High | II | |||||
| Anti-tuberculosis | 300 | NA | 0.01 | 11.27 | 3.79 | −0.89 | 68.01 | NA | High | Low | III | |||
| Antianginal | 10 | NA | 4.82E-05 | NA | −1.75 | 58.92 | NA | High | Low | III | ||||
| Antihypertensive | 200 | NA | 0.04 | 7.91 | 9.2 | −0.42 | 95.6 | NA | High | High | I | |||
| Antiretroviral | 150 | NA | 0.17 | 13.83 | 4.41 | −0.71 | 113.45 | BCRP, MRP1 | High | Low | III | |||
| Anthelmintic | 40 | NA | 0.0067 | 8.81 | −0.15 | 40.9 | NA | High | High | I | ||||
| Antiparkinsonism | 250 | NA | 0.09 | 2.24 | 9.3 | −0.27 | 103.78 | NA | High | High | I | |||
| Antihypertensive | 20 | NA | 0.02 | 2.18 | 10.51 | −1.32 | 133 | MDR1, PEPT1 | High | Low | III | |||
| Antihypertensive | 25 | NA | 0.49 | 4.24 | 3.1 | 0.89 | 92.5 | MDR1, OAT1 | High | High | I | |||
| Anthelmintic | 100 | NA | 20 | 10.29 | 5.02 | 2.77 | 84.08 | MDR1 | Low | High | II | |||
| Anticancer | 50 | 0.03 | 8.46 | 2.4 | 0.37 | 85.2 | MRP4, MRP5 | High | High | I | ||||
| Antidiabetic | 500 | NA | 0.002 | 13.1 | −4.31 | 88.99 | OCT1, OCT2 | High | Low | III | ||||
| Antidote | 250 | NA | 0.04 | 2.23 | 9.26 | −2.13 | 88.6 | OCTN2 | High | Low | III | |||
| Anticancer | 10 | NA | 6.20E-05 | 3.54 | 5.09 | NA | 211 | BCRP, MDR1, MRP1-7, OAT1-4, OATP1B1, OATP1B3, OATP1C1 | High | Low | III | |||
| Antihypertensive | 500 | NA | 0.3 | 2.28 | 9.3 | −2.37 | 103.78 | PEPT1 | High | Low | III | |||
| Antiemetic | 10 | NA | 0.0002 | 13.28 | 9.62 | −7.8 | 67.59 | NA | High | Low | III | |||
| Anti-Amoebic | 400 | NA | 0.2 | 2.58 | −1.01 | 78.94 | NA | High | Low | III | ||||
| Analgesic | 30 | NA | 0.0005 | 9.72 | 8.14 | −1.77 | 52.93 | MDR1 | High | Low | III | |||
| Antibacterial | 500 | NA | 0.73 | 1.2 | 5.95 | 0.33 | 70.5 | NA | High | High | I | |||
| Antiretroviral | 250 | NA | 291.54 | 9.58 | 7.53 | 5.44 | 127.2 | BCRP, MDR1, OATP1A2, OATP1B1 | Low | High | II | |||
| Antidote | 15 | NA | 0.00019 | NA | −3.03 | 29.54 | MDR1 | High | Low | III | ||||
| Antiretroviral | 200 | NA | 1.37 | 10.93 | 4.74 | 1.84 | 58.12 | NA | Low | High | II | |||
| Anthelmintic | 500 | NA | 1801.8 | NA | 5.4 | 95.15 | NA | Low | High | II | ||||
| Antibacterial | 100 | NA | 0.28 | 7.69 | 1.2 | −0.41 | 120.73 | NA | High | High | I | |||
| Antianginal | 6.4 | 0.02 | NA | 2.22 | 165 | NA | High | High | I | |||||
| Antifungal | 200 | NA | 26.6 | NA | −0.42 | 319.61 | NA | Low | High | II | ||||
| Antiulcer | 20 | NA | 0.004 | 9.08 | 4.61 | 2.15 | 96.3 | BCRP, MDR1, MRP3 | High | High | I | |||
| Analgesic | 500 | NA | 0.19 | 9.86 | 0.34 | 49.33 | NA | High | High | I | ||||
| Antidote | 250 | NA | 0.096 | 2.13 | 11.54 | −1.57 | 102.12 | NA | High | Low | III | |||
| Antiepileptic | 30 | NA | 0.18 | 7.88 | 1.66 | 75.27 | NA | High | High | I | ||||
| Antibacterial | 500 | NA | 0.02 | 2.62 | −1.47 | 121.24 | NA | High | Low | III | ||||
| Antiepileptic | 100 | NA | 4 | 8.33 | 2.52 | 58.2 | MDR1, MRP2 | Low | High | II | ||||
| Antihypertensive | 2 | NA | 0.016 | 6.47 | −1.25 | 107 | BCRP, MDR1, OCT1−3 | High | Low | III | ||||
| Antiallergic | 5 | NA | 0.15 | 12.47 | 1.49 | 94.83 | MDR1 | High | High | I | ||||
| Antimalarial | 7.5 | NA | 0.00015 | 10.38 | −0.41 | 60.17 | NA | High | High | I | ||||
| Antiarrythmic | 250 | NA | 0.017 | 9.86 | −1.43 | 58.4 | MDR1, OATP1A2, OCT1-3, OCTN1,2 | High | Low | III | ||||
| Anticancer | 50 | NA | 0.0006 | 7.46 | 0.11 | 53.2 | NA | High | High | I | ||||
| Antipsychotic | 5 | 1.34 | 7.82 | 2.42 | 35 | NA | Low | High | II | |||||
| Antiparkinsonism | 5 | NA | 2.03 | 10.48 | 0.84 | 23.5 | NA | Low | High | II | ||||
| Antiallergic | 25 | NA | 0.04 | 8.98 | 2.04 | 31.78 | MDR1 | High | High | I | ||||
| Antihypertensive | 160 | NA | 0.01 | 13.84 | 9.14 | 0.28 | 41.49 | MDR1, NTCP, OCT2 | High | High | I | |||
| Anticancer | 100 | NA | 0.2 | 7.63 | 0.54 | 1.36 | 73.22 | NA | High | High | I | |||
| Anthelmintic | 250 | NA | 0.012 | 10.97 | −0.49 | 43.84 | NA | High | Low | III | ||||
| Anti-tuberculosis | 500 | NA | 0.09 | 13.91 | −0.37 | 68.87 | NA | High | High | I | ||||
| Muscle relaxant | 60 | NA | 0.0005 | NA | −4.31 | 29.54 | NA | High | Low | III | ||||
| Antiarrythmic | 200 | 5.7 | 13.05 | 9.13 | 1.35 | 45.6 | BSEP, MDR1, OAT3, OATP1A2, OATP1B1, OCT1,2, OCTN1,2 | Low | High | II | ||||
| Antimalarial | 200 | NA | 0.03 | 13.05 | 9.13 | 0.54 | 45.59 | MDR1, OATP1A2, OATP1C1, OCT1,2, OCTN1,2 | High | High | I | |||
| Antipsychotic | 3 | NA | 0.017 | 7.91 | 1.01 | 61.9 NA | High | High | I | |||||
| Anti-tuberculosis | 600 | NA | 1.71 | NA | −1.75 | 217 | MDR1, MRP1,2,5, OATP1A2, OATP1B1, OATP1B3, OATP2B1 | Low | Low | IV | ||||
| Antiretroviral | 100 | NA | 1063.8 | 11047 | 3.48 | 5.28 | 202.26 | BCRP, MDR1, MRP1,2, OATP1A2, OATP1B1 | Low | High | II | |||
| Antiasthmatic | 4 | NA | 0.000016 | 9.83 | 9.22 | −2.84 | 72.72 | NA | High | Low | II | |||
| Antiretroviral | 200 | NA | 16 | NA | 2.84 | 166.75 | BCRP, MDR1,2, OATP1A2, OATP1B1 | Low | High | II | ||||
| Antiparkinsonism | 5 | NA 0.78 7.53 | 0.78 | 7.53 | 1.42 | 3.2 | MDR1 | High | High | I | ||||
| Diuretic | 100 | NA | 44.3 | NA | 3.12 | 85.74 | MDR1 | Low | High | II | ||||
| Antiretroviral | 40 | NA | 0.009 | 9.57 | −0.86 | 78.87 | NA | High | Low | III | ||||
| Antibacterial | 500 | NA | 0.29 | 2.88 | 1.86 | 0.35 | 149.69 | NA | High | High | I | |||
| Anticancer | 20 | NA | 479.04 | 8.69 | 6.2 | 12.5 | BCRP, BSEP, MDR1 | Low | High | II | ||||
| Antiasthmatic | 270 | NA | 0.25 | 8.6 | 1.05 | −0.18 | 69.3 | NA | High | High | I | |||
| Anti-tuberculosis | 50 | NA | 0.2 | NA | NA | 112 | NA | High | Low | III | ||||
| Anticancer | 40 | NA | 0.004 | 7.44 | 3.09 | −0.4 | 111 | MRP4 | High | High | I | |||
| Antifungal | 500 | NA | 0.0004 | NA | −0.27 | 106 | NA | High | High | I | ||||
| Antipsychotic | 5 | NA | 1.63 | 7.82 | 4.04 | 35 | NA | Low | High | II | ||||
| Antibacterial | 300 | NA | 0.17 | 7.34 | −0.42 | 105.51 | MDR1 | High | High | I | ||||
| Antiepileptic | 300 | NA | 0.005 | 4.82 | −1.65 | 100.27 | OAT3, OCTN2 | High | Low | III | ||||
| Antihypertensive | 240 | NA | 0.85 | 9.03 | 2.91 | 64 | BCRP, BSEP, MDR1, MRP1-4,7, OATP1A2, OCT1, OCTN1,2, PGP | High | High | I | ||||
| Anti-coagulant | 5 | NA | 0.01 | 4.5 | 1.91 | 63.6 | NA | High | High | I | ||||
| Antiretroviral | 0 75 | NA | 4.96E-07 | 4.47 | −1.51 | 88.2 | NA | High | Low | III | ||||
| Antiretroviral | 100 | NA | 0.1 | NA | −0.53 | 91.23 | PEPT1 | High | Low | III | ||||
-Do (dose number) calculated from solubility data taken from ref. (9)
Do (dose number) calculated from solubility data taken from ref. (10)
Do (dose number) calculated from predicted solubility data, ACD/Labs
The maximal dose strength on the list of national essential medicines of Pakistan;
pKa values were taken from ref. 12
Calculated log D6.0 values at pH 6 using ACD/Labs
PSA calculated from ACD/Labs
Transporter interaction taken from ref. 25
BCRP: Breast cancer resistance protein
BSEP: Bile salt export pump; MDR: Multidrug transporter
MRP: Multidrug resistance protein; NA: not available
OAT: Organic anion transporter
OATP: Organic anion-transporting polypeptide
OCTN: Organic cation transporter
OST: Organic solute transporter
PEPT: Peptide transporter
Pgp: P-glycoprotein.
Solubility data correlation: ACD/Labs, experimental water solubility DrugBank, ALOGPS and reliable experimental solubility.
| Drug | Dose (mg) | D | D | D | Solubility Class 1 | Solubility Class 2 | Solubility Class 3 | Reliable experimental solubility |
|---|---|---|---|---|---|---|---|---|
| 300 | 2.9268293 | 0.0155844 | 0.99173554 | Low | High | High | High | |
| 500 | 0.002 | 0.4347826 | 1.36986301 | High | High | Low | High | |
| 200 | 2.1052632 | 0.4938272 | 0.08810573 | Low | High | High | High | |
| 100 | 0.0101807 | 0.7029877 | 0.06802721 | High | High | High | High | |
| 5 | 0.1666667 | 0.01639344 | High | High | High | |||
| 100 | 0.0004 | 0.0296296 | 0.93240093 | High | High | High | High | |
| 25 | 0.0001 | 0.02212389 | High | High | High | |||
| 200 | 10 | 45.19774 | 5.26315789 | Low | Low | Low | Low | |
| 250 | 4.3478261 | 0.4 | 2.1691974 | Low | High | Low | High | |
| 150 | 0.0220345 | 56.603774 | 34.2857143 | High | Low | Low | High | |
| 200 | 0.0722022 | 0.16 | 0.98039216 | High | High | High | High | |
| 1000 | 0.2805049 | 287.76978 | 75.1879699 | High | Low | Low | High | |
| 30 | 0.0022822 | 0.0133333 | 0.20797227 | High | High | High | High | |
| 0.5 | 0.0285714 | 4.44E-05 | 0.07246377 | High | High | High | High | |
| 25 | 0.0011682 | 0.002 | 0.00662252 | High | High | High | High | |
| 100 | 1.1428571 | 1.0526316 | 1.4084507 | Low | Low | Low | Low | |
| 5 | 1 | 0.4 | 1.63934426 | High | High | Low | High | |
| 0.625 | 0.0054348 | 0.01968504 | High | High | High | |||
| 100 | 0.5405405 | 0.6349206 | 0.7751938 | High | High | High | High | |
| 1 | 0.4 | 0.01793722 | High | High | High | |||
| 50 | 0.7407407 | 200 | 0.14388489 | High | Low | High | High | |
| 40 | 0.0230548 | 26.666667 | 1.3559322 | High | Low | Low | Low | |
| 250 | 1492.5373 | 115.74074 | 19.8412698 | Low | Low | Low | Low | |
| 50 | 0.1724138 | 0.07575758 | High | High | High | |||
| 25 | 0.2439024 | 0.1428571 | 0.04464286 | High | High | High | High | |
| 400 | 0.7804878 | 32.653061 | 23.3918129 | High | Low | Low | Low | |
| 400 | 53.333333 | 106.66667 | 33.1950207 | Low | Low | Low | Low | |
| 250 | 0.0942507 | 23.562677 | 0.3030303 | High | Low | High | High | |
| 0.75 | 0.4207574 | 1.4705882 | 0.51457976 | High | Low | High | High | |
| 0.1 | 0.0997506 | 0.0038095 | 0.04454343 | High | High | High | High | |
| 500 | 0.002 | 0.88888889 | High | High | High | |||
| 250 | 0.149925 | 1 | 0.44247788 | High | High | High | High | |
| 500 | 0.2816901 | 84.459459 | 0.008 | High | Low | High | High | |
| 250 | 291.54519 | 523.560209 | Low | Low | Low | |||
| 10 | 1.3333333 | 2.25988701 | Low | Low | Low | |||
| 100 | 0.2857143 | 5.0327126 | 0.96385542 | High | Low | High | Low | |
| 500 | 0.1966568 | 0.1428571 | 0.48192771 | High | High | High | High | |
| 250 | 0.0968054 | 0.009009 | 0.21505376 | High | High | High | High | |
| 250 | 0.0125723 | 1 | 2.20264317 | High | High | Low | High | |
| 100 | 0.625 | 0.3603604 | 1.44927536 | High | High | Low | High | |
| 100 | 4 | 12.5 | 5.62587904 | Low | Low | Low | Low | |
| 5 | 0.1538462 | 0.0896861 | 0.08368201 | High | High | High | High | |
| Primaquine | 15 | 0.0003165 | 1.06382979 | High | Low | High | ||
| 25 | 0.0478469 | 4.08163265 | High | Low | High | |||
| 40 | 0.0029602 | 2.2857143 | 2.01511335 | High | Low | Low | High | |
| 50 | 0.1149425 | 0.1666667 | 0.42918455 | High | High | High | High | |
| 400 | 0.0759734 | 0.1066667 | 0.01707577 | High | High | High | High | |
| 60 | 0.0005417 | 0.23076923 | High | High | High | |||
| 5 | 0.0001868 | 0.2361275 | 0.0304414 | High | High | High | High | |
| 100 | 1063.8298 | 317.460317 | Low | Low | Low | |||
| 4 | 0.000016 | 5.3333333 | 0.00744186 | High | Low | High | High | |
| 200 | 16 | 323.88664 | Low | Low | Low | |||
| 40 | 0.0091376 | 0.016 | 0.00395062 | High | High | High | High | |
| 400 | 1.509434 | 2.6229508 | 3.48583878 | Low | Low | High | Low | |
| 300 | 0.2836879 | 0.24 | 0.05240175 | High | High | High | High | |
| 50 | 0.0009126 | 0.0004 | 13.0718954 | High | High | Low | High | |
| 200 | 0.1152738 | 0.0661157 | 1.30081301 | High | High | Low | Low | |
| 500 | 0.0091258 | 0.004 | 130.718954 | High | High | Low | Low | |
| 300 | 0.3243243 | 0.024 | 0.07361963 | High | High | High | High |
1-Do (dose number) calculated from predicted solubility data, ACD/Labs
2 Do (dose number) calculated from solubility data obtained from DrugBank database
3 Do (dose number) calculated from predicted solubility data, ALOGPS
Reliable experimental solubility, were taken from ref. 13.
Solubility and permeability classification comparing the list of national essential medicines (NEML) of Pakistan and classification of the WHO's essential medicines model list (EML)
| Drug | WHO | NEML Dose (mg) | WHO | NEML Solubility class | Comment | WHO | NEML Permeability class | Comment |
|---|---|---|---|---|---|---|---|---|
| 500 | 300 | High | High | High | Low | Classified as low permeability drug based on reliable data | ||
| 200 | 200 | High | Low | Low | Low | |||
| 400 | 200 | Low | Low | inconclusive | High | |||
| 100 | 300 | High | High | High | Low | Classified as low permeability drug based on reliable data | ||
| 5 | 5 | High | High | High | High | |||
| 25 | 50 | High | High | High | High | |||
| 5 | 5 | High | High | High | High | |||
| 500 | 500 | High | Low | classified as high solubility based on incomplete data | High | Low | Classified as high permeability based on incomplete data | |
| 100 | 100 | High | High | Low | Low | |||
| 200 | 200 | Low | Low | High | High | |||
| 400 | 100 | Low | High | NEML dose is lower than that of WHO | inconclusive | Low | ||
| 250 | 250 | High | Low | Low | High | Classified as low permeability based on reliable data | ||
| 150 | 150 | High | High | High | High | |||
| 4 | 4 | High | High | inconclusive | High | |||
| 100 | 100 | High | High | inconclusive | High | |||
| 250 | 250 | High | High | inconclusive | Low | |||
| 25 | 25 | High | High | inconclusive | High | |||
| 1000 | 250 | High | High | Low | Low | |||
| 100 | 50 | Low | High | NEML dose is lower than that of WHO | High | High | ||
| 5 | 10 | High | Low | NEML dose is higher than that of WHO | High | High | ||
| 400 | 400 | High | High | Low | Low | |||
| 0.25 | 0.25 | High | High | High | High | |||
| 500 | 500 | Low | Low | inconclusive | High | |||
| 100 | 100 | High | High | High | Low | Classified as low permeability drug based on reliable data | ||
| 200 | 50 | Low | Low | inconclusive | High | |||
| 2.5 | 10 | High | High | Low | High | Both log D60 and PSA indicated high permeability | ||
| 250 | 500 | Low | High | classified as low solubility based on incomplete data | Low | High | Classified as low permeability based on incomplete data | |
| 400 | 400 | High | High | Low | Low | |||
| 40 | 40 | Low | High | inconclusive | High | |||
| 5 | 5 | Low | High | Classified as low solubility based on inconclusive data | inconclusive | High | ||
| 250 | 500 | Low | Low | High | High | |||
| 2 | 5 | inconclusive | High | Low | High | |||
| 50 | 25 | High | High | Low | High | Classified as low permeability drug based on reliable data | ||
| 25 | 50 | High | High | Low | High | Classified as low permeability drug based on reliable data | ||
| 400 | 600 | Low | Low | High | High | |||
| 400 | 400 | Low | Low | inconclusive | High | |||
| 300 | 300 | High | High | inconclusive | Low | |||
| 5 | 10 | High | High | inconclusive | Low | |||
| 150 | 150 | High | High | High | Low | Both log D60 and PSA indicated low permeability | ||
| 150 | 40 | High | High | inconclusive | High | |||
| 250 | 250 | High | High | High | High | |||
| 25 | 25 | High | High | inconclusive | Low | |||
| 500 | 100 | Low | Low | inconclusive | High | |||
| 250 | 250 | High | High | High | Low | Classified as high permeability based on incomplete data | ||
| 500 | 500 | High | High | Low | Low | |||
| 250 | 500 | High | High | Low | Low | |||
| 10 | 10 | High | High | Low | Low | |||
| 500 | 400 | High | High | High | Low | Classified as high permeability drug based on reliable data | ||
| 10 | 30 | High | High | inconclusive | Low | |||
| 250 | 250 | inconclusive | Low | inconclusive | High | |||
| 15 | 15 | High | High | Low | Low | |||
| 200 | 200 | Low | Low | High | High | |||
| 500 | 500 | Low | Low | inconclusive | High | |||
| 100 | 100 | Low | High | High | High | |||
| 200 | 200 | inconclusive | Low | inconclusive | High | |||
| 500 | 500 | High | High | High | High | |||
| 250 | 250 | High | High | Low | Low | |||
| 100 | 30 | High | High | High | High | |||
| 250 | 500 | High | High | High | Low | Classified as high permeability drug based on reliable data | ||
| 100 | 100 | Low | Low | High | High | |||
| 25 | 5 | High | High | High | High | |||
| 15 | 7.5 | High | High | High | High | |||
| 25 | 25 | High | High | High | High | |||
| 40 | 160 | High | High | High | High | |||
| 50 | 100 | High | High | High | High | |||
| 250 | 250 | Low | High | classified as low solubility based on inconclusive data | inconclusive | Low | ||
| 400 | 500 | High | High | inconclusive | High | |||
| 300 | 200 | High | High | High | High | |||
| 300 | 600 | Low | Low | High | Low | Classified as high permeability based on incomplete data | ||
| 100 | 100 | Low | Low | inconclusive | High | |||
| 4 | 4 | High | High | High | Low | |||
| 200 | 200 | Low | Low | inconclusive | High | |||
| 25 | 100 | inconclusive | Low | inconclusive | High | |||
| 40 | 40 | High | High | High | Low | PSA can indicate high permeability | ||
| 500 | 500 | Low | High | classified as low solubility based on inconclusive data | Low | High | Inconclusive data | |
| 200 | 300 | Low | High | High | High | |||
| 500 | 300 | High | High | High | Low | Classified as high permeability drug based on reliable data | ||
| 80 | 240 | Low | High | classified as low solubility based on inconclusive data | High | High | ||
| 5 | 5 | High | High | High | High | |||
| 300 | 100 | High | High | High | Low | Classified as high permeability drug based on reliable data |
Ref. (13)
Ref. (16)
Comparison of Permeability prediction based on log P, log D and PSA, by using metoprolol or labetalol as internal standard.
| Drug | Log | Log D6.0 | PSA | Internal standard: Metoprolol | Internal standard: Labetalol | Reliable experimental solubilityΘ | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Log | Log D6.0 cutoff “−1.48” | PSA cutoff “65” | Log | Log D6.0 cutoff “−0.42” | PSA cutoff “95.6” | |||||
| 0.72 | 0.03 | 96.95 | Low | Low | Low | Low | High | Low | Low | |
| 1.19 | −1.24 | 63.6 | Low | Low | High | Low | Low | High | Low | |
| −1.76 | −1.76 | 109.83 | Low | Low | Low | Low | Low | Low | Low | |
| −1.33 | −3.81 | 74.69 | Low | Low | Low | Low | Low | High | Low | |
| 1.08 | 1.07 | 156.79 | Low | Low | Low | Low | High | Low | High | |
| 0.1 | −2.73 | 84.58 | Low | Low | Low | Low | Low | High | Low | |
| 0.27 | −2.02 | 96.41 | Low | Low | Low | Low | Low | Low | Low | |
| 2.67 | 2.67 | 46.33 | High | High | High | High | High | High | High | |
| 1.02 | 1.02 | 115.38 | Low | Low | Low | Low | High | Low | Low | |
| 4.69 | 1.2 | 28.16 | High | Low | High | High | High | High | High | |
| 0.26 | −1.14 | 114.19 | Low | Low | Low | Low | Low | Low | Low | |
| 2.53 | −0.81 | 138.04 | High | Low | Low | High | Low | Low | Low | |
| 1.2 | −0.99 | 41.93 | Low | Low | High | Low | Low | High | Low | |
| 0.92 | 0.92 | 83.09 | Low | Low | Low | Low | High | High | Low | |
| 0.23 | 0.23 | 51.38 | Low | Low | High | Low | High | High | High | |
| 0.94 | 0.94 | 94.56 | Low | Low | Low | Low | High | High | High | |
| 2.96 | 2.96 | 32.67 | High | High | High | High | High | High | High | |
| 0.85 | 0.85 | 203.06 | Low | Low | Low | Low | High | Low | High | |
| −0.54 | −3.06 | 181.62 | Low | Low | Low | Low | Low | Low | High | |
| 3.58 | 1.99 | 118.21 | High | High | Low | High | High | Low | Low | |
| 0.5 | 0.5 | 71.79 | Low | Low | Low | Low | High | High | High | |
| 3 | 0.26 | 131.01 | High | Low | Low | High | High | Low | Low | |
| 3.53 | 3.53 | 71.06 | High | High | Low | High | High | High | High | |
| 1 | 0.56 | 63.83 | Low | Low | High | Low | High | High | Low | |
| −0.07 | −0.07 | 135.12 | Low | Low | Low | Low | High | Low | Low | |
| 3.72 | 2.12 | 37.3 | High | High | High | High | High | High | High | |
| 2.88 | 2.76 | 118.03 | High | High | Low | High | High | Low | Low | |
| −0.22 | −0.27 | 103.78 | Low | Low | Low | Low | High | Low | High | |
| 3.92 | 3.92 | 37.3 | High | High | High | High | High | High | High | |
| 5.93 | 3.38 | 92.78 | High | High | Low | Low | High | High | Low | |
| −2.31 | −4.31 | 88.99 | Low | Low | Low | Low | Low | High | Low | |
| 0.12 | −2.37 | 103.78 | Low | Low | Low | Low | Low | Low | Low | |
| −1.01 | −1.01 | 78.94 | Low | Low | Low | Low | Low | High | High | |
| 6.98 | 5.44 | 127.2 | High | High | Low | Low | High | Low | Low | |
| 2.97 | 2.96 | 110.45 | High | High | Low | High | High | Low | High | |
| −0.4 | −0.41 | 120.73 | Low | Low | Low | Low | High | Low | High | |
| 0.34 | 0.34 | 49.33 | Low | Low | High | Low | High | High | Low | |
| 0.93 | −1.57 | 102.12 | Low | Low | Low | Low | Low | Low | Low | |
| 1.88 | −1.47 | 121.24 | High | Low | Low | Low | Low | Low | High | |
| 1.67 | 1.66 | 75.27 | High | High | Low | Low | High | High | High | |
| 2.52 | 2.52 | 58.2 | High | High | High | High | High | High | High | |
| 1.49 | 1.49 | 94.83 | High | High | Low | Low | High | High | High | |
| 2.67 | −0.41 | 60.17 | High | Low | High | High | High | High | High | |
| 4.78 | 2.04 | 31.78 | High | High | High | High | High | High | Low | |
| 3.1 | 0.28 | 41.49 | High | Low | High | High | High | High | High | |
| 1.37 | 1.36 | 73.22 | High | Low | Low | Low | High | High | Low | |
| −0.37 | −0.37 | 68.87 | Low | Low | Low | Low | High | High | High | |
| −4.31 | −4.31 | 29.54 | Low | Low | High | Low | Low | High | Low | |
| −2.02 | −3.48 | 155.05 | Low | Low | Low | Low | Low | Low | High | |
| 5.28 | 5.28 | 202.26 | High | High | Low | Low | High | Low | Low | |
| 0.01 | −2.84 | 72.72 | Low | Low | Low | Low | Low | High | High | |
| 4.44 | 2.84 | 166.75 | High | High | Low | High | High | Low | Low | |
| −0.86 | −0.86 | 78.87 | Low | Low | Low | Low | Low | High | High | |
| 0.89 | 0.49 | 106.6 | Low | Low | Low | Low | High | Low | High | |
| −0.17 | −0.18 | 69.3 | Low | Low | Low | Low | High | High | High | |
| −1.61 | −1.65 | 100.27 | Low | Low | Low | Low | Low | Low | Low | |
| 0.79 | −0.42 | 105.51 | Low | Low | Low | Low | High | Low | High | |
| −1.61 | −1.65 | 100.27 | Low | Low | Low | Low | Low | Low | High | |
| −0.53 | −0.53 | 91.23 | Low | Low | Low | Low | Low | High | High | |
Figure 1Biopharmaceutical classification system with drugs on the list of national essential medicines of Pakistan.
Permeability data correlation: Log D6.0 ACDLabs, PSA and experimental Caco-2 permeability coefficient (Papp).
| Drug | Papp | Permeability class | Log D6.0 | Permeability class | Prediction | PSA cutoff “95.6” | Prediction | PSA cutoff “65” | Prediction | Log | Prediction | Log | Prediction |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.4×10−6 | Low | −1.24 | Low | c | High | fp | High | fp | Low | c | Low | c | |
| 5.3×10−7 | Low | −2.73 | Low | c | High | fp | Low | c | Low | c | Low | c | |
| 2.15×10−5 | High | 2.67 | High | c | High | c | High | c | High | c | High | c | |
| 1.6×10−5 | High | 0.49 | High | c | High | c | High | c | High | c | High | c | |
| 1.37×10−6 | Low | −1.14 | Low | c | Low | c | Low | c | Low | c | Low | c | |
| 2.34×10−5 | High | 1.87 | High | c | High | c | Low | fn | High | c | Low | fn | |
| 3.34×10−5 | High | 2.96 | High | c | High | c | High | c | High | c | High | c | |
| 5×10−5 | High | 0.85 | High | c | Low | fn | Low | fn | Low | fn | Low | fn | |
| 4.9×10−5 | High | 2.64 | High | c | High | c | Low | fn | High | c | High | c | |
| 3.33×10−6 | Low | 0.26 | High | fp | Low | c | Low | c | High | fp | High | fp | |
| 3.68×10−5 | High | 3.53 | High | c | High | c | Low | fn | High | c | High | c | |
| 5.1×10−7 | Low | −0.07 | High | fp | Low | c | Low | c | Low | c | Low | c | |
| 5.25×10−5 | High | 2.12 | High | c | High | c | High | c | High | c | High | c | |
| 2.04×10−5 | High | 0.3 | High | c | High | c | Low | fn | High | c | High | c | |
| 1.5×10−5 | Ref | −0.42 | High | c | High | c | Low | fn | High | c | High | c | |
| 2.67×10−5 | High | 2.52 | High | c | High | c | High | c | High | c | High | c | |
| 2.75×10−5 | High | 0.28 | High | c | High | c | High | c | High | c | High | c | |
| 2.04×10−5 | High | 0.54 | High | c | High | c | High | c | High | c | High | c | |
| 5.5×10−7 | Low | 2.84 | High | fp | Low | c | Low | c | High | fp | High | fp | |
| 1.29×10−7 | Low | 0.35 | High | fp | Low | c | Low | c | High | High | fp | ||
| 4.47×10−5 | High | −0.18 | High | c | High | c | Low | fn | Low | fn | Low | fn | |
| 2.63×10−5 | High | 2.91 | High | c | High | c | High | c | High | c | High | c | |
| 6.93×10−6 | Low | −0.53 | Low | c | High | Low | c | Low | c | Low | c |
Calculated log D values at pH 6 using ACD/Labs
Taken from ref. 15; Ж taken from ref. 19
Ref: reference; c: correct; fp: false positive; fn: false negative.